

# Ilaria Cavazzana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3715992/publications.pdf>

Version: 2024-02-01

67  
papers

2,265  
citations

236833

25  
h-index

214721

47  
g-index

69  
all docs

69  
docs citations

69  
times ranked

2742  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2328-2336.	0.4	214
2	Anti-Ro/SSA and La/SSB antibodies. <i>Autoimmunity</i> , 2005, 38, 55-63.	1.2	204
3	Novel aspects of Sjögren's syndrome in 2012. <i>BMC Medicine</i> , 2013, 11, 93.	2.3	134
4	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	0.4	133
5	Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. <i>Arthritis Research and Therapy</i> , 2012, 14, R97.	1.6	124
6	Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. <i>Journal of Immunological Methods</i> , 2016, 433, 1-5.	0.6	109
7	Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. <i>British Journal of Rheumatology</i> , 2002, 41, 1357-1366.	2.5	98
8	Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies. <i>Journal of Rheumatology</i> , 2011, 38, 1329-1334.	1.0	94
9	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	1.0	93
10	Complement activation in anti-phospholipid syndrome: A clue for an inflammatory process?. <i>Journal of Autoimmunity</i> , 2007, 28, 160-164.	3.0	74
11	Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. <i>Lupus</i> , 2009, 18, 735-739.	0.8	68
12	Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. <i>Lupus</i> , 2008, 17, 727-732.	0.8	58
13	Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. <i>Journal of Rheumatology</i> , 2002, 29, 1393-7.	1.0	53
14	Anti-Th/To Are Common Antinucleolar Autoantibodies in Italian Patients with Scleroderma. <i>Journal of Rheumatology</i> , 2010, 37, 2071-2075.	1.0	52
15	Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2008, 8, 104-106.	2.5	50
16	Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. <i>Lupus</i> , 2017, 26, 1197-1204.	0.8	50
17	Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression. <i>Autoimmunity Reviews</i> , 2009, 8, 580-584.	2.5	46
18	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	2.5	46

#	ARTICLE	IF	CITATIONS
19	The 2016 classification criteria for primary Sjogren's syndrome: what's new?. BMC Medicine, 2017, 15, 69.	2.3	43
20	Complement Activation and Pregnancy Failure. Clinical Reviews in Allergy and Immunology, 2010, 39, 153-159.	2.9	39
21	Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus, 2014, 23, 672-677.	0.8	35
22	Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 2180-2185.	1.0	33
23	Anti-RNA Polymerase III Antibodies as a Risk Marker for Early Gastric Antral Vascular Ectasia (GAVE) in Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 1544.1-1544.	1.0	31
24	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.4	30
25	Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures. Immunologic Research, 2017, 65, 150-156.	1.3	27
26	The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. Clinical Reviews in Allergy and Immunology, 2017, 52, 88-98.	2.9	26
27	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatology, The, 2021, 3, e166-e168.	2.2	25
28	Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clinical Reviews in Allergy and Immunology, 2023, 64, 412-430.	2.9	23
29	Update on Antiphospholipid Syndrome: Ten Topics in 2017. Current Rheumatology Reports, 2018, 20, 15.	2.1	22
30	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis Research and Therapy, 2012, 14, R2.	1.6	19
31	C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. NeuroMolecular Medicine, 2019, 21, 150-159.	1.8	19
32	Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors. Lupus, 2019, 28, 210-216.	0.8	17
33	Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. Clinical and Experimental Rheumatology, 2017, 35, 303-308.	0.4	16
34	Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety. Journal of Rheumatology, 2015, 42, 193-195.	1.0	15
35	Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases. Frontiers in Medicine, 2022, 9, 849086.	1.2	13
36	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. Journal of Rheumatology, 2022, 49, 176-185.	1.0	12

#	ARTICLE	IF	CITATIONS
37	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 572876.	2.2	11
38	Aseptic meningitis occurring during anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 732-4.	0.4	10
39	In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. <i>European Journal of Dermatology</i> , 2014, 24, 349-355.	0.3	9
40	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 3176-3188.	0.9	9
41	Semiquantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e152-e152.	0.5	8
42	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 91-97.	0.4	8
43	Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 1074-1081.	0.8	7
44	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
45	Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study. <i>Autoimmunity Reviews</i> , 2021, 20, 102757.	2.5	6
46	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3020-3023.	3.0	6
47	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 240-250.	2.9	6
48	A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 118-21.	0.4	6
49	Clinical evolution of antisynthetase syndrome after SARS-CoV2 infection: a 6-month follow-up analysis. <i>Clinical Rheumatology</i> , 2022, 41, 2601-2604.	1.0	6
50	Diastolic dysfunction in rheumatoid arthritis: a usual travel-mate?. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.3	4
51	Unusual association between pure red cell aplasia and primary Sjögren's syndrome: a case report. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 309-11.	0.4	3
52	Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 676-83.	0.4	3
53	Antibodies against antigens related to scleroderma in a cohort of patients with morphea. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 451-458.	0.1	2
54	Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 352.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Anti-MJ/NXP-2 antibodies are the most common specificity in a cohort of adult caucasian patients with dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A49.2-A49.	0.5	1
56	AB0234â€¦Nailfold capillary (NC) evaluation in patients with anti-KU antibodies and various connective tissue diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 650.17-651.	0.5	1
57	Centromere Autoantibodies. , 2014, , 179-183.		1
58	Treatment and functional outcome of patients with cystoid macular edema: a single-center experience. <i>Clinical Rheumatology</i> , 2015, 34, 791-794.	1.0	1
59	AB0806â€¦The impact of dysphagia in idiopathic inflammatory myositis: an online survey of highly-specialised centres. , 2018, , .		1
60	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 91-97.	0.4	1
61	Ventricular-arterial coupling in systemic lupus erythematosus women without cardiovascular risk factors. <i>Lupus</i> , 2022, , 096120332210934.	0.8	1
62	Anti-MIT3 antibodies in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A84-A84.	0.5	0
63	AB0239â€¦Autoantibody profile in a cohort of adult patients with inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 651.4-651.	0.5	0
64	Dr. Reggia, <i>et al,</i> reply. <i>Journal of Rheumatology</i> , 2015, 42, 1995.1-1995.	1.0	0
65	SAT0205â€¦Failure of the Switch from the Intravenous to the Subcutaneous Formulation of Abatacept due to a Disease Reactivation: Our Experience. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 731.1-731.	0.5	0
66	PS5:95â€¦Circulating angiogenic t-cells are reduced in patients with systemic lupus erythematosus with high disease activity and without known cardiovascular risk factors. , 2018, , .		0
67	P036â€¦B cell number reduction has a predictive value for response to belimumab in a cohort of patients with systemic lupus erythematosus. , 2019, , .		0